Citation Impact
Citing Papers
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
2011 Standout
The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase
2005
Insertion of Green Fluorescent Protein into Nonstructural Protein 5A Allows Direct Visualization of Functional Hepatitis C Virus Replication Complexes
2004 StandoutNobel
Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells
2002
TOR Signaling in Growth and Metabolism
2006 Standout
Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition
2004
2- and 3-substituted imidazo[1,2-a]pyrazines as inhibitors of bacterial type IV secretion
2014
Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors
2005
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Farnesyltransferase Inhibitors
2001
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
Actin' up: RhoB in cancer and apoptosis
2001
Ras oncogenes: split personalities
2008
The farnesyltransferase inhibitor lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt
2004
High‐Throughput Screening for Terpene‐Synthase‐Cyclization Activity and Directed Evolution of a Terpene Synthase
2013 StandoutNobel
Sphingolipids and their metabolism in physiology and disease
2017 Standout
Searching for the elusive targets of farnesyltransferase inhibitors
2003
Therapeutic Strategies for Targeting Ras Proteins
2011
A Bulky Biaryl Phosphine Ligand Allows for Palladium‐Catalyzed Amidation of Five‐Membered Heterocycles as Electrophiles
2012
Farnesyltransferase inhibitors: promises and realities
2002
A computationally engineered RAS rheostat reveals RAS–ERK signaling dynamics
2016 StandoutNobel
Detection of Peptides, Proteins, and Drugs That Selectively Interact With Protein Targets
2002 StandoutNobel
Post-prenylation-processing enzymes as new targets in oncogenesis
2005
Farnesyl transferase inhibitors as anticancer agents
2002
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
2002 Standout
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan
2002
Targeting cancer with small molecule kinase inhibitors
2008 Standout
FoxM1 is required for execution of the mitotic programme and chromosome stability
2005 Standout
The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling
2005
Chemotherapy and the war on cancer
2005 Standout
Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies
2000
Targeting RAS signalling pathways in cancer therapy
2003 Standout
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Poly(ADP-ribose): novel functions for an old molecule
2006 Standout
Enzyme Activities of the Ceramide Synthases CERS2–6 Are Regulated by Phosphorylation in the C-terminal Region
2016
Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells
2005 StandoutNobel
Molecular characterisation of MEK1/2- and MKK3/6-like mitogen-activated protein kinase kinases (MAPKK) from the fox tapeworm Echinococcus multilocularis
2009
Perspectives on farnesyl transferase inhibitors in cancer therapy
2003
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Revealing the world of RNA interference
2004 StandoutNatureNobel
Centromere Proteins Cenpa, Cenpb, and Bub3 Interact with Poly(ADP-ribose) Polymerase-1 Protein and Are Poly(ADP-ribosyl)ated
2002
Mitosin/CENP-F as a Negative Regulator of Activating Transcription Factor-4
2005
Search for Protein Farnesyltransferase Inhibitors of Microbial Origin: Our Strategy and Results as well as the Results Obtained by Other Groups
2007 StandoutNobel
Slaying RAS with a synthetic lethal weapon
2010 StandoutNobel
Biological effects of essential oils – A review
2007 Standout
Synthesis of Tris-Heterocycles via a Cascade IMCR/Aza Diels-Alder + CuAAC Strategy
2019
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
2004
The spindle-assembly checkpoint in space and time
2007 Standout
The integrated stress response
2016 Standout
3d Transition Metals for C–H Activation
2018 Standout
Recent Fascinating Aspects of the CuAAC Click Reaction
2020 StandoutNobel
Contribution of Organofluorine Compounds to Pharmaceuticals
2020 Standout
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Palmitoylation of oncogenic NRAS is essential for leukemogenesis
2010
A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design
2015
Comprehensive Mutational Analysis of the Moloney Murine Leukemia Virus Envelope Protein
2001
A Molecular View of Kinetochore Assembly and Function
2017
Applications of Deuterium in Medicinal Chemistry
2019
High‐Throughput Screening for Terpene‐Synthase‐Cyclization Activity and Directed Evolution of a Terpene Synthase
2013 StandoutNobel
Echinococcosis: Advances in the 21st Century
2019 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
The Origin of Chalcogen-Bonding Interactions
2017 Standout
Precise Modulation of CO2 Sorption in Ti8Ce2–Oxo Clusters: Elucidating Lewis Acidity of the Ce Metal Sites and Structural Flexibility
2024 StandoutNobel
Longer metaphase and fewer chromosome segregation errors in modern human than Neanderthal brain development
2022 StandoutNobel
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors
2007
The Catalytic Asymmetric Intermolecular Prins Reaction
2021 StandoutNobel
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
2006
Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition
2005 Standout
Click-Chemistry Based High Throughput Screening Platform for Modulators of Ras Palmitoylation
2017 StandoutNobel
Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer
2003
Moloney Murine Leukemia Virus Envelope Protein Subunits, gp70 and Pr15E, Form a Stable Disulfide-Linked Complex
1998
Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis
2002
Centromere-associated protein-E is essential for the mammalian mitotic checkpoint to prevent aneuploidy due to single chromosome loss
2003
BindingDB Entry 2025: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
2007
Applications of Palladium-Catalyzed C–N Cross-Coupling Reactions
2016 Standout
Farnesyl Diphosphate Analogues with ω-Bioorthogonal Azide and Alkyne Functional Groups for Protein Farnesyl Transferase-Catalyzed Ligation Reactions
2007
Molecular mechanisms of resistance of leukemia to imatinib mesylate
2003
International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.
2002 Standout
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
2004
Applications of Fluorine in Medicinal Chemistry
2015 Standout
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies
2003
Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor.
2001
Bioorthogonale Chemie – oder: in einem Meer aus Funktionalität nach Selektivität fischen
2009 StandoutNobel
Works of Kimberly Gray being referenced
The Farnesyl Transferase Inhibitor SCH 66336 Induces a G2 → M or G1 Pause in Sensitive Human Tumor Cell Lines
2001
Analysis of Mutations within the Cytoplasmic Domain of the Moloney Murine Leukemia Virus Transmembrane Protein
1997
Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules
2000
Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors
2010
Synthesis and SAR studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivity
2012
Structural basis of CX-4945 binding to human protein kinase CK2
2010
Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors
2010
Expression and purification of phosphorylated and non-phosphorylated human MEK1
2006
Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors
2010
Aurora Kinase Inhibitors Based on the Imidazo[1,2-a]pyrazine Core: Fluorine and Deuterium Incorporation Improve Oral Absorption and Exposure
2010